Friday May 19, 2017
The Future of Medicine Congress will kick off with an in depth examination of the science of perinatal derived stem cells and products derived from perinatal tissue sources. The Perinatal Stem Cell Society focuses on perinatal tissue sources because of the enormous therapeutic potential of these tissue sources and the ability of these medical waste products to be used to save and improve lives. Additionally, the society will continue to highlight that these perinatal tissue sources are readily available today as 99% of all births are throw into the garbage rather then being used to treat patients. In the years ahead, as the worldwide demand for cellular therapies grows at the exceptional pace we anticipate it will, perinatal tissues and products will be required to meet patient demand. Friday May 19th will be a very exciting day at the Future of Medicine Congress.
Faculty Confirmed to Present on Perinatal Stem Cell and Tissue Topics:
Director, Wake Forest Institute for Regenerative Medicine, H. Boyce Professor and Chair of Urology, Wake Forest School of Medicine Professor. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. His work focuses on growing human cells, tissues and organs.
Dr. Atala works with several journals and serves in various roles, including Editor-in-Chief of: Stem Cells- Translational Medicine; Current Stem Cell Research and Therapy; Therapeutic Advances in Urology; and BioPrinting. Dr. Atala is a recipient of awards, including the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, the World Technology Award in Health and Medicine, the Samuel D. Gross Prize in Surgical Research, the Innovation Award from the Society of Manufacturing Engineers, the Rocovich Gold Medal, and the Edison Science/Medical Award for work in 3D Bioprinting. In 2011 he was elected to the Institute of Medicine of the National Academy of Sciences, and in 2014 was inducted to the National Academy of Inventors as a Charter Fellow. Dr. Atala’s ongoing work has been described in the lay press. Dr. Atala’s work was listed in 2007 as Time Magazine’s top 10 medical breakthroughs of the year, by Discover Magazine in 2007 as the Number 1 Top Science Story of the Year in the field of medicine, by Smithsonian Magazine in 2010 as one of 40 things to know about the next 40 years, by Time Magazine in 2011 as one of the top 5 medical breakthroughs of the year, by the Huffington post in 2011 as one of 18 great ideas for the future, and by Time Magazine in 2013 as one of 5 discoveries that will change the future of organ transplants.
Dr. Atala was named by Scientific American in 2010 as a Medical Treatments Leader of the Year for his contributions to the fields of cell, tissue and organ regeneration, by U.S. News & World Report in 2009 in as one of 14 Pioneers of Medical Progress in the 21st Century, by the American Association of Retired Persons in 2012 as one of the 50 influential people who will make life better, and by Scientific American in 2015 as one of the world’s most influential people in biotechnology. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the Bioengineering Consortium, the National Cancer Institute’s National Cancer Advisory Board, and was the Founder of the Regenerative Medicine Foundation. Dr. Atala heads a team of over 450 physicians and researchers. Over twelve applications of technologies developed in Dr. Atala’s laboratory have been used clinically. He is the editor of fourteen books, including Principles of Regenerative Medicine, 3D Biofabrication, Essentials of Stem Cell Biology, and Methods of Tissue Engineering. He has published more than 500 journal articles and has applied for or received over 250 national and international patents.
Professor of Obstetrics and Gynecology, Tufts University School of Medicine
Former President, International Cord Blood Society (ICBS)
Medical Consultant, Auxocell Laboratories, Inc.
Curtis L. Cetrulo, MD has a profound passion for stem cells and pursues this passion with the same excitement and energy that he has brought with him at every stage of his career. Since 1984 until the present, Dr. Cetrulo has been a Professor of Obstetrics and Gynecology at Tufts University School of Medicine. He is one of the two founding members and is the current President of the International Cord Blood Society (ICBS), a non-profit organization founded in 1995. In 2007, Dr. Cetrulo guest edited an edition of the Journal “Stem Cell Reviews” that focused on Pregnancy related stem cells. Dr. Cetrulo is currently a medical consultant for Auxocell Laboratories, Inc. a company that focuses on stem cells obtained from the Wharton’s Jelly of the human umbilical cord. From 1996 until 2005, Dr. Cetrulo was the medical director of New England Cord Blood Bank, Inc. From 1992- 1994, Dr. Cetrulo was the Chairman of the Obstetrical Quality Assurance Committee at New England Medical Center. In 1992, he was named the Director of Regional Perinatal Program at New England Medical Center and from 1975-1992, Dr. Cetrulo was the Director of Maternal-Fetal Medicine at St. Margaret’s Hospital in Boston. In 1990, Dr. Cetrulo was named the President of Medical Staff at St. Margaret’s Hospital. In 1977, Dr. Cetrulo was board certified in Maternal Fetal Medicine. He was the first OB/GYN to be board certified in Maternal Fetal Medicine in Boston, Massachusetts. Dr. Cetrulo completed his Maternal Fetal Medicine fellowship at the University of Southern California Medical Center in Los Angeles, California in 1975. He completed his Obstetrics/Gynecology residency program at the University of Colorado in Denver, Colorado in 1973. Dr. Cetrulo graduated from the New Jersey College of Medicine in 1969. He did his undergraduate work at Columbia University (1965) where he was the captain of the 1964 NCAA champion Fencing team.
George & Cynthia Mitchell Distinguished Chair in Neurosciences, Department of Pediatric Surgery
Director, Program in Children’s Regenerative Medicine, Department of Pediatric Surgery
Co-Director, Texas Trauma Institute
The Pediatric Translational Laboratories and Pediatric Program in Regenerative Medicine is a multi-disciplinary effort that addresses problems that originate with traumatic injury and the consequences of resuscitation and critical care. The Program focuses on progenitor cell based therapy (stem cells) for traumatic brain injury, and related neurological injuries (hypoxic-ischemic encephalopathy, stroke, spinal cord injury), recently completing the first acute, autologous cell therapy treatment Phase I study for traumatic brain injury in children. Dr. Cox has served on scientific study sections/review groups for the National Institutes of Health, American Heart Association, Veterans Affairs MERIT Awards, Department of Defense, Congressionally Directed Medical Research Programs, as well as National Research Programs in Canada, Singapore, and the Czech Republic. He is the author of over 100 scientific publications, 20 book chapters, and is the editor of a text in press entitled, Progenitor Cell Therapy for Neurological Injury.
Fellow, AIMBE, Fellow, BMES. Carol Ann and David D Flanagan Professor and Wallace H. Coulter Distinguished Fellow, Director, Center for ImmunoEngineering at Georgia Tech The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University The Parker H. Petit Institute for Bioscience and Bioengineering Georgia Institute of Technology
Dr. Krishnendu (Krish) Roy received his undergraduate degree from the Indian Institute of Technology (India) followed by his MS from Boston University and his PhD in Biomedical Engineering from Johns Hopkins University. Following his PhD, he joined Zycos Inc., a start-up biotechnology company where he served first as a Scientist and then as a Senior Scientist in the Drug Delivery Research group. Dr. Roy left his industrial position to join The University of Texas at Austin in 2002, where he was most recently Professor and Fellow of the Cockrell Chair in Engineering Excellence. He left UT-Austin in July of 2013 to move to Georgia Tech. where he is currently the Carol Ann and David D. Flanagan Professor and Wallace H. Coulter Distinguished Faculty Fellow. At Georgia Tech, he also serves as Director of the Center for ImmunoEngineering, a consortium of 30+ faculty focused on using engineering tools and methodologies to understand and modulate the immune system in health and disease. He is also currently the Technical Lead of the Cell Manufacturing Consortium, a national public-private partnership, focused on addressing the challenges and solutions for large scale manufacturing of therapeutic cells. Dr. Roy’s research interests are in the areas of controlled drug and vaccine delivery technologies, Immuno-engineering, stem cell engineering and cell manufacturing, with particular focus in biomedical materials with applications in cancer and immunotherapies. In recognition of his seminal contribution to these fields, Dr. Roy has been elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and Fellow of the Biomedical Engineering Society (BMES). In addition, Dr. Roy has received numerous awards and honors including Young Investigator Awards from both the Controlled Release Society (CRS) and The Society for Biomaterials (SFB), the Young Scientist Award from HSEMB, NSF CAREER award, Global Indus Technovator Award from MIT, the CRS Cygnus Award etc. He has also received the translational research award from the Coulter foundation and the bioengineering grant from the Whitaker Foundation. Dr. Roy’s research has been supported through numerous grants from the NIH and NSF as well as the Cancer Prevention and Research Institute of Texas (CPRIT). He is also twice the recipient of Best Teacher Award given by the Biomedical Engineering Students at The University of Texas. He serves as a member of the Editorial Boards of the Journal of Controlled Release and the European Journal of Pharmaceutics and Biopharmaceutics.
Chief Scientific Officer, Auxocell Laboratories, Inc.
Rouzbeh R. Taghizadeh, PhD, has dedicated more than 15 years to bringing stem cell-based therapies to clinical practice. He earned his Ph.D. in Stem Cell Bioengineering in 2006 from the Massachusetts Institute of Technology (MIT). In 2008, Dr. Taghizadeh co-founded Auxocell Laboratories, Inc. in 2008 and currently serves as Auxocell’s Chief Scientific Officer. At Auxocell, Dr. Taghizadeh developed novel methods and technologies to establish the collection, processing, and banking of stem cells from the human umbilical cord for eventual utilization in stem cell based therapies, regenerative medicine, and other clinical applications. Most notably, Dr. Taghizadeh and his team developed the novel single-use, disposable solid tissue processing system – the patented Auxocell Processing System (AC:Px™). Dr. Taghizadeh has contributed to numerous peer-reviewed publications, book chapters, and patents and is an editor of the 2nd edition of Perinatal Stem Cells.
Dr. Sean V. Murphy received his PhD from Monash University, Melbourne, Australia and is currently a Research Fellow at the Wake Forest Institute for Regenerative Medicine in North Carolina, USA. His research focuses on the clinical application of perinatal cells and tissues for the treatment of injury and disease. Dr. Murphy has received numerous awards and fellowships, most notably an American Lung Association Senior Research Training Fellowship, and an American Australian Association Sir Keith Murdoch Fellowship.
Dr. Murphy is Director/Secretary and Co-founder of the Perinatal Stem Cell Society, serves on the editorial board of multiple international journals and has recently published the book Perinatal Stem Cells: Biology and Clinical Applications which provides a comprehensive overview of the therapeutic application of perinatal stem cells in both the clinical and preclinical settings.
Founder and Director of the Parent’s Guide to Cord Blood Foundation
Frances Verter, PhD, is the founder and director of the Parent’s Guide to Cord Blood Foundation, incorporated in the United States as a 501(c)(3) charity. Since 1998, PGCB Foundation has been educating parents about their cord blood options, supporting both public donation and private storage for the family.
Despite the name “Parent’s Guide” and its humble start, PGCB Foundation has evolved to perform multiple roles in the cord blood industry.
- For parents worldwide, parentsguidecordblood.org is the leading internet resource helping families to learn about cord blood banking. In the United States, the number of expectant mothers who receive an educational brochure from PGCB Foundation in their prenatal education packet is about 40% the number of births from which cord blood is banked.
- For healthcare providers, PGCB Foundation provides educational fact sheets at parentsguidecordblood.org.
- For laboratory professionals, PGCB Foundation has issued a Cord Blood Industry Report at cordbloodindustryreport.org.
In order to keep pace with the ever growing science and technology of this field, the industry report covers banking of perinatal stem cells from additional sources such as cord tissue.
For more information about the Parents Guide to Cord Blood Foundation please visit www.parentsguidecordblood.org.
Saturday May 20, 2017
Our goal for the Saturday session of this meeting is to acknowledge that there are many types of stem cell treatments taking place in the US and to guide clinicians on the very best methods available. We will have talks on Allograft products from Perinatal Tissues, talks on Adipose processing methods and results from these type of stem cell treatments in the clinic as well as bone marrow and PRP. Our goal is to help advance the field so that the best outcomes are made available to patients by bringing in the world’s leading and credible experts who successfully use stem cell treatments in their clinics to treat patients.
Faculty Confirmed to Lecture on the Stem Cell Options Being Used in the Clinic Today,
Plastic and Reconstructive Surgery, Massachusetts General Hospital
Dr. Cetrulo is a nationally-respected clinical microsurgeon and educator, and a national leader in vascularized composite allotransplantation.
Dr. Cetrulo graduated from Stanford University in 1992 and Tufts University School of Medicine in 1999. Following general surgery residency training, a plastic surgery research fellowship, plastic surgery residency training and hand and microsurgery fellowship training, Dr. Cetrulo practiced reconstructive microsurgery and hand surgery at the University of Southern California Medical Center (USC). He also performed pediatric reconstructive microsurgery, burn reconstruction, cleft lip/palate surgery, and pediatric hand surgery at the Shriners Hospital for Children-Los Angeles from 2007-2009. In addition, Dr. Cetrulo established and directed a translational research laboratory dedicated to composite tissue allograft research. Dr. Cetrulo participated in many medical missions while at USC.
In 2009, Dr. Cetrulo joined the Division of Plastic and Reconstructive Surgery of the Massachusetts General Hospital (MGH) and the Massachusetts General Hospital for Children, as well as the staff of Shriners Hospital for Children-Boston. Dr. Cetrulo’s surgical practice is dedicated to preforming cutting–edge complex adult and pediatric reconstructive microsurgery, as well as to hand surgery, breast reconstruction, and burn reconstruction. Dr. Cetrulo has published numerous clinical research contributions to the microsurgery literature.
Dr. Cetrulo established of the first Vascularized Composite Allotransplantation Service at MGH, from inception to regulatory board approval to performance of MGH’s first hand transplantation. Dr. Cetrulo’s hand transplant case has been distinguished by the patient’s superior functional outcome compared to other hand transplant recipients throughout the world, as well as for widening the applicability of this procedure for burned amputees.
Dr. Cetrulo also serves as the Senior Investigator and Head of the Vascularized Composite Tissue Allotransplantation Laboratory at the Transplantation Biology Research Center, Massachusetts General Hospital. The TBRC laboratory is investigating tolerance induction strategies for vascularized composite tissue allografts (VCA) in the immunogenetically-defined MGH miniature swine model as well as in non-human primate models. Current research efforts are directed toward use of mixed hematopoietic chimerism to induce transplantation tolerance to VCA and toward exploring the immunologic mechanisms involved in tolerance and rejection of the skin component of VCA. TBRC recently published an important contribution to the field: the first demonstration of immunologic tolerance of all components of a VCA in a large animal, preclinical model.
Adam William Anz, M.D. is an Orthopaedic surgeon who is fellowship trained in sports related injuries focusing on knee surgery, hip arthroscopy, and orthobiologics. He has many peer-reviewed publications and presentations with a special interest in cartilage regeneration.
His main goals are to keep patients as active as possible in the least invasive way and constantly improve our Orthopaedic techniques. Dr. Anz graduated summa cum laude from Vanderbilt University with a degree in mathematics and Alpha Omega Alpha from the University of South Alabama College of Medicine. His orthopaedic surgery residency training was at Wake Forest University in Winston- Salem, North Carolina, and he completed a sports fellowship at the Steadman Clinic in Vail, Colorado where he learned complex knee surgery from Drs. Steadman and
Laprade and hip arthroscopy from Dr. Philippon. Dr. Anz has numerous Othopaedic journal publications and a strongest interest in biologic augmentation of our current surgical techniques. In 2009, he first visited with Dr. Khay Yong Saw in Kuala Lumpur, Malaysia, who has pioneered a method to regenerate cartilage using a patients own stem cells, and has returned for a total of four visits to collaborate with Dr. Saw. Currently, Drs. Saw and Anz are initiating a multicenter trial involving this cell technology to advance its status with the US FDA.
Additional current projects include biomechanical strength testing of new arthroscopic suture techniques, repair of the biceps femoris, and synovial stem cell augmentation of ACL reconstruction.
Chief Sciences Officer, Senior Associate Dean for Experimental and Cellular Therapeutics, Director of the Interdisciplinary Stem Cell Institute (ISCI), and Louis Lemberg Professor of Medicine at the University of Miami Miller School of Medicine
Dr. Hare is an expert in cardiovascular medicine and specializes in heart failure, myocardial infarction, inflammatory diseases of the heart, and heart transplantation. He is an internationally acknowledged pioneer in the field of stem cell therapeutics for human heart disease, currently seeing and evaluating patients from all over the world for this new experimental therapy.
Dr. Hare is the founding director of the Interdisciplinary Stem Cell Institute, an Institute devoted to basic scientific and translational work in the field of stem cell therapy and regenerative medicine. The Institute houses 70 faculty members and 15 independent research groups. Dr. Hare led the first randomized allogeneic mesenchymal stem cell (MSC) clinical trial for patients with myocardial infarction and is principal investigator of multiple other trials for heart failure and cardiovascular disease. He has pioneered the use of all allogenic MSCs for multiple disease areas. Under his leadership, ISCI now has active programs in cancer biology, cardiology, aging, neonatology, skin diseases, bone diseases, neurologic diseases, ophthalmology, and a program devoted to the ethics of stem cell therapy.
Dr. Hare has published more than 260 original research articles, editorials, and review articles, and is the recipient of seven grants from the National Institutes of Health. He holds 10 FDA Investigational New Drug applications for cell-based therapy in patients with heart disease, including the first in the United States for Idiopathic Pulmonary Fibrosis and Aging Frailty. He is the recipient of three active NIH RO1’s and is the PI of the UM National Heart Lung and Blood Institute Cardiac Cell Therapy Trial Network (CCTRN) center; together these awards fund ~$3M in basic and translational research annually. Under his leadership, ISCI has been awarded $10M from The Starr Foundation and a $25M award from The Soffer Family. Dr. Hare recently completed a term as chair of the Cardiac Contractility and Heart Failure study section of the National Institute of Health (NIH), chairs the Stem Cell Working Group of the American Heart Association (AHA), and is the immediate, past Chair of the AHA Basic Cardiovascular Science Council.
Educated at the University of Pennsylvania (1984), Johns Hopkins University School of Medicine (1988), The Brigham and Women’s Hospital (1994), and Harvard Medical School, Dr. Hare spent 12 years on the faculty at Johns Hopkins University School of Medicine where he rose to the rank of Professor of Medicine and Biomedical Engineering, and Director of the Cardiac Transplant and Heart Failure program in 2004 before joining the faculty at the University of Miami Miller School of Medicine in 2007. Dr. Hare is an elected member of the American Association of Physicians (2011) and the Association of University Cardiologists (2007). Dr. Hare is the inventor of 10 (three issued) United States patents, and his research discoveries have led to the founding of four biotechnology companies, all of which have received initial funding.
Sports and Regenerative Medicine
Dr. Dennis Lox practices Sports and Regenerative Medicine in the Tampa Bay Metro area and Beverly Hills, California. Dr Lox has authored 2 medical texts, 8 book chapters, and frequently lectures around the world. Dr. Lox is an expert in the use of stem cell applications to sports and osteoarthritis. Dr. Lox treats a very diverse patient base, from professional athletes, to weekend warriors, and aging patients who wish to maintain a high quality of life. Dr. Lox has treated patients from around the world, desiring to maintain their health.